Abstract I In nt tr ro od du uc ct ti io on n. . The Deletion (D) rather than Insertion (I) variant of the angiotensin-converting enzyme (ACE) gene is associated with higher circulating ACE activity. Meanwhile, coronary risk rises with the menstrual nadir in oestrogen levels, exogenous oestrogen reduces serum ACE activity (with a greater reduction the higher the baseline ACE activity), and pharmacological reduction in ACE activity is cardioprotective. Alterations in coronary risk associated with the menstrual cycle may thus be mediated through (genotype-dependent) changes in ACE activity.We have examined this hypothesis. M Ma at te er ri ia al ls s a an nd d m me et th ho od ds s. . Twenty-three healthy female subjects (12 II, 11 DD genotype) were studied. None were taking oral contraceptive agents. Blood was assayed for oestrogen, follicle stimulating hormone (FSH), luteinising hormone (LH), progesterone and ACE activity every three days throughout their menstrual cycle. Results ACE activity was unrelated to oestrogen, FSH or LH during the menstrual cycle, irrespective of ACE genotype. C Co on nc cl lu us si io on ns s. . The increase in myocardial ischaemia during low oestrogen phases of the menstrual cycle does not appear mediated through a fall in serum ACE activity.
Introduction
Coronary atherosclerosis is less prevalent in premenopausal women than in men, 1-2 and acute coronary events are more frequent during the oestrogen nadir coinciding with the menses. 3 Amongst those with known coronary disease, ischaemic events are commonest [4] [5] [6] and the threshold for exercise-induced myocardial ischaemia lowest 7 when oestrogen levels are cyclically lowest. Oestrogen-mediated changes in angiotensin-converting enzyme (ACE) might partly mediate such phenomena.
Rodent ACE activity rises after oophrectomy in rodents, 8 and falls with subsequent oestrogen replacement in both circulation and tissues such as the kidney, aorta, [9] [10] heart, lung, adrenal and brain. 10 In humans, pregnancy-related rises in oestrogen are associated with rises in ACE activity [11] [12] whilst exogenous oestrogen administration to post-menopausal women (PMW) is consistently and durably associated with reduced serum ACE activity [13] [14] [15] [16] [17] [18] [19] [20] [21] with the greatest reductions amongst those with the highest initial ACE levels. 14 Such effects may be mediated through inhibition of ACE messenger ribonucleic synthesis 18 or alterations in the cleavage of membrane-bound ACE. Meanwhile, the presence (Insertion, I) rather than absence (Deletion, D) of a 287 bp fragment in the ACE gene is associated with lower serum 22 and tissue 23 ACE activity, and (although this is debated 24, 25 ) with reduced cardiovascular risk. [26] [27] [28] Pharmacological ACE inhibition also reduces cardiovascular risk in diabetes, or established coronary disease and its sequaelae. [29] [30] [31] [32] Thus, low oestrogen levels (during the menstrual cycle and post-menopausally) are associated with increased cardiovascular risk, and reduced ACE activity with reduced cardiovascular risk; ACE activity falls with exogenous oestrogen administration (perhaps more so the higher the initial ACE activity); and ACE activity is dependent upon ACE I/D genotype. Such findings suggest the hypothesis that serum ACE activity rises as oestrogen levels fall during the menstrual cycle, and that the magnitude of such an association will be ACE genotype-dependent. We have examined this hypothesis.
Materials and methods
The study was conducted in accordance with the Declaration of Helsinki and had appropriate ethics committee approval. Written informed consent was obtained from all participants.
Subjects
Eligible for inclusion were non-smoking healthy females with a stable alcohol consumption of <18 units/week. All were required to have regular menstrual cycles ( < 3 days variation between cycles) and menses lasting between three and six days. Exclusion criteria included shift-work, more than 7-hours structured exercise per week, any current regular medication use, hormonal contraceptive therapy within the preceding six months, any history of gynaecological or fertility disorder and any significant medical or psychiatric disease.
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DNA extraction and genotyping
At recruitment, a buccal mouth swab was obtained, and pressed upon a FTA ® Whatman Micro card (Whatman, Middlesex, UK), according to the manufacturer's instructions. From this, DNA was obtained and prepared for polymerase chain reaction analysis by washing in FTA ® purification reagent followed by deionised-water. ACE genotype was determined using a threeprimer method as previously described. 33 Presence of the I allele produces a band size of 65 bp, and the D allele 85 bp. Products were separated on 7.5% polyacrylamide gel stained with ethidium bromide using the microarray diagonal gel electrophoresis system. Genotypes were confirmed by two independent technicians blind to subject outcome. Those with II or DD genotype were selected for study.
Study protocol
Venous sampling was performed at 08:30 hours on the first day of subject menses. Further samples were taken between 08:30 and 09:30 hours every three days thereafter until the start of their next menses or day 34, whichever was sooner. All subjects refrained from alcohol and exercise for 24-hours prior to sampling. All blood samples were immediately centrifuged at 3,500 g for 10 minutes and the serum separated and stored at -20°C until analysis en bloc.
Biochemical assays
Progesterone and estradiol were determined by radioimmunoassay (Diagnostic Systems Laboratories (DSL) Texas, USA) with a sensitivity of 0.1 ng/ml and 4.7 pg/ml respectively. The intraand interassay coefficients of variation (CV) were, respectively: progesterone, 3.3% at 5.5 ng/ml and 3.3% at 11.4 ng/ml; estradiol, 5.3% at 156.4 pg/ml and 8.1% at 409.2 pg/ml.
Luteinising hormone (LH) and follicle stimulating hormone (FSH) were determined by an immunoradiometric assay (DSL, Texas) with a sensitivity of 0.12mIU/ml and 0.11mIU/ml respectively. The intra-and interassay CV were, respectively: LH, 6.8% at 6.2 mIU/ml and 7.3% at 4.8 mIU/ml; FSH, 3.6% at 6.7 mIU/ml and 7.5% at 5.8 mIU/ml. ACE activity was assayed by a modified fluorometric method using carbobenzoxyphenyl-alanyl-histidyl-leucine (Z-Phe-His-Leu) as substrate as previously described. 34 All assays were performed in duplicate, from which the derived mean was used in all data analysis. Results were expressed as nmol His-Leu ml -1 min -1 .
The intra-and interassay CV were, respectively 1.9-5.6% and 9.4%.
Statistical analysis
Differences in ACE activity were tested by repeated measures analysis of variance to take account of lack of independence within-subjects.
The correction factor used is that of Geisser and Greenhouse. 35 ACE activity was normally distributed and oestrogen, FSH and LH values were log-transformed before analysis to give normal distributions. Pearson correlation coefficients were used to assess the association of mean ACE levels with peak oestrogen, FSH and LH. The association between oestrogen and ACE over the cycle was examined by regressing ACE on logeoestrogen for each subject and comparing the average regression coefficient in each group by unpaired t-test.
Results
Of 176 subjects screened, twelve subjects of II genotype and twelve of DD genotype were randomly selected from those meeting criteria for entry. Of these, one subject had an abnormal 1 ). No significant correlation was found between mean ACE activity and peak levels of oestrogen, FSH and LH (r=-0.16, p=0.49; r=0.08, p=0.74; r=0.12, p=0.67 for oestrogen, FSH and LH respectively). ACE did not vary over time and the correlation of oestrogen peak level and ACE measured at the same time (r=-0.18, p=0.42) is similar to that seen between peak oestrogen and mean ACE.
Paper
The average regression coefficients in DD (0.03 [2.70] ) and II subjects (-0.59 [2.42]) do not differ from zero (p=0.97 and 0.42 respectively), offering no evidence that ACE and oestrogen change together over the cycle in either group. The coefficients do not differ by genotype (p=0.57) and therefore the association of ACE and oestrogen over the cycle is similar in both II and DD subjects.
The cross-sectional time series regression model further confirmed that there was no association between ACE and oestrogen over time (regression coefficient (se)=-0.37 (0.43) p=0.40) and that the association did not differ by genotype.
Discussion
This is the first report to have examined changes in ACE activity during the human menstrual cycle. Reducing ACE activity reduces cardiovascular risk, and ACE activity falls with exogenous oestrogen administration, perhaps moreso the higher the initial ACE activity. Despite this background, the increase in cardiovascular risk observed during the low oestrogen phases of the menstrual cycle [3] [4] 7 does not appear to be mediated via a corresponding cyclic rise in circulating ACE activity. It should be pointed out, however, that the study had power (80% at 5% level) to detect a two-fold difference in oestradiol between ACE genotypes. Such power was based on pharmacological data and, as such, smaller differences might not have been identified. Much larger studies might need to be prospectively performed in order to identify these more minor modulations.
We cannot, exclude the possibility that falling oestrogen levels mediate an increase in cardiovascular risk through a divorced rise in vascular tissue ACE activity divorced from that found in serum. In addition, a causative coupling of ovarian ACE expression and oestrogen secretion/ menstruation may help explain the null result when compared to the influence of exogenous oestrogen administration: local RAS components exist in human decidua, 36 ovary 37 and endometrium, 38, 39 endometrial ACE expression rises during the late secretory phase and menses, 40 and angiotensin II-like immunoreactivity and AT 1 -and AT 2 -receptor subtypes also vary cyclically. [40] [41] [42] 
Conclusions
Human serum ACE activity does not vary overall, or by ACE I/D genotype, during the normal menstrual cycle. Further exploration of a putative role of exogenous oestrogen in regulation of tissue ACE expression seems worthwhile. 
Journal of the Renin-Angiotensin-Aldosterone System
